FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:647-648 February 7, 2008 Number 6 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article PubMed Citation

To the Editor: We report on two cases of melanoma in women with multiple sclerosis who were treated with natalizumab (Tysabri, Biogen Idec and Elan Pharmaceuticals), a humanized monoclonal antibody against ₄ integrins. Patient 1 was a 46-year-old woman who, shortly after receiving her first dose of natalizumab, noticed a rapidly changing mole on her shoulder; on evaluation, it proved to be a thick, nonulcerated melanoma with metastatic disease in the regional lymph nodes. Patient 2 was a 45-year-old woman who had a long-standing ocular nevus that developed into an ocular melanoma after the administration of several doses of natalizumab (. . . [Full Text of this Article]

Related Letters:

More on Melanoma with Transdifferentiation
Panzara M. A., Bozic C., Sandrock A. W., Mullen J. T., Vartanian T. K., Atkins M. B.
Extract | Full Text | PDF  
N Engl J Med 2008; 359:99-100, Jul 3, 2008. Correspondence

This article has been cited by other articles:

• Panzara, M. A., Bozic, C., Sandrock, A. W., Mullen, J. T., Vartanian, T. K., Atkins, M. B. (2008). More on Melanoma with Transdifferentiation. NEJM 359: 99-100 [Full Text]